PRESBYOND Results and How Long They Last

What success means

"How successful is it" is a reasonable question with no single answer, because four different things are usually being asked at once.

• Uncorrected distance vision. How well you see far away without glasses.
• Uncorrected near vision. How well you read without glasses, at what distance and in what light.
• Spectacle independence. How often you actually reach for glasses, which is a behaviour rather than a measurement.
• Satisfaction. Whether you would do it again, which depends on expectations as much as on acuity.

A study can measure the first two precisely and the second two approximately, and the gap between them is where dissatisfaction lives. Someone can have excellent measured vision and still be unhappy, because the thing they wanted was to read a menu in a dim restaurant rather than to score well on a chart.

What the published studies report

Two 2026 series are the most directly relevant recent evidence, and an earlier one-year series is included because it reports the complaint patients mention most often. The figures are those studies' own reported outcomes, printed because attributing them is more honest than paraphrasing them into vague optimism. They are not this site's estimate of your result.

What the two series have in common is more informative than either alone: both report predictable refraction, both report that most patients reduce their dependence on glasses, and both report retreatment in a minority. Neither followed patients long enough to describe what happens as presbyopia continues to progress.

How to read those numbers

Three cautions apply to every figure above.

They are retrospective. The patients were not randomly assigned, the protocols were not identical, and the surgeons knew what they were treating. That is normal for surgical case series and it means the results describe what happened at those clinics, not what would happen in a trial.

They are not comparisons. Neither study randomises PRESBYOND against conventional monovision, so nothing here establishes that one is better than the other. The comparison page is explicit about that limit.

They are short. Six and twelve months are enough to describe refractive stability and early satisfaction. They are not enough to describe decade-scale change, and presbyopia is a decade-scale process.

Manufacturer claims, separately

ZEISS states that many patients can read without glasses the same day, that vision normally stabilises within two to three weeks, and that it may continue to improve over the following months. Those statements come from the manufacturer's patient information, not from the studies above, and they describe the intended experience of the product.

They are plausible as an expectation and useless as a standard. A patient whose near vision is still settling at eight weeks has not failed the treatment; they are at the slower end of a normal distribution that no single sentence can describe.

Presbyopia keeps progressing

This is the part most often missing from a results page, and it is the part that determines what happens in ten years. The treatment changes the cornea. It does not change the lens, and the lens continues to lose flexibility with age.

In practice that means near vision can decline again, and reading glasses may become necessary later even after a good result. That is not a complication and it is not a failure of the surgery; it is the ageing process continuing. Anyone planning a permanent procedure on eyes that will keep changing should hear that before the operation rather than after it.

Retreatment and refinement

A residual prescription can be refined once refraction has stabilised, usually by lifting the original flap and treating again. The published series report retreatment in a minority of patients, and both found it more common in long-sighted eyes than in short-sighted ones.

Refinement is not guaranteed to be possible. It requires remaining corneal tissue and a regular surface, and it is another operation with its own risks. The questions worth asking before the first procedure are whether refinement is included in the fee, whether there is a time limit, and what happens if your cornea cannot support it.

Asking a clinic for its own data

A study from Western Australia is interesting. Your surgeon's own outcomes are relevant. The question that produces a real answer is not "what is your success rate" but:

• How many of these have you performed, and over what period?
• How do you record outcomes, and at what intervals do you review patients?
• What proportion of your patients have needed refinement, and how do you define it?
• What do you do when a patient has not adapted by three months?

A clinic that measures its results can answer those. A clinic that does not will answer with a percentage from a brochure, which is the one number that tells you least.

What no evidence can tell you